Shimozaki, K., Fukuda, K., Ooki, A., Nakayama, I., Yoshino, K., Tamba, M., . . . Yamaguchi, K. (2024, September). Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: Real-world data analysis. ESMO Gastrointestinal Oncology.
Chicago Style (17th ed.) CitationShimozaki, K., et al. "Safety and Efficacy of First-line Nivolumab Plus Chemotherapy for HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Real-world Data Analysis." ESMO Gastrointestinal Oncology Sep. 2024.
MLA引文Shimozaki, K., et al. "Safety and Efficacy of First-line Nivolumab Plus Chemotherapy for HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Real-world Data Analysis." ESMO Gastrointestinal Oncology, Sep. 2024.